Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX321 in Recurrent Glioblastoma Multiforme
NCT00797940Phase 2Withdrawn
- Sponsor
- Sophiris Bio Inc.
- Start
- Jan 2009
- Primary completion
- Dec 2010
- Modality
- Immunotoxins, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of interleukin-4 pe38kdel in glioblastoma multiforme (GBM), sponsored by Sophiris Bio Inc. Primary endpoint: Overall Survival at 6 Months. Planned start Jan 2009; status: withdrawn.
02
Drugs
interleukin-4 pe38kdel
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00797940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00797940.